VANCOUVER, Wash., March 28, 2016 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that clinical findings from the Company’s PRO 140 monotherapy phase 2b study will be presented in an oral slide session at the ASM Microbe 2016 Conference from June 16 – 20 in Boston, MA.

Presentation details are as follows:

Title: PRO 140 SC Monotherapy Provides Long-Term, Full Virologic Suppression in HIV Patients
Authors: P.J. Maddon, K. Dhody, U. Kowalczyk, K. Kazempour, N. Pourhassan, J. Lalezari
Date/Time: Monday, June 20 from 9:00 – 9:15 a.m. ET
Session: Antiretrovirals for Prevention and Treatment
Location: Boston Convention and Exhibition Center, Meeting Room 156A

About ASM Microbe 2016
ASM Microbe 2016 is the merger of the American Society for Microbiology’s two premier events, the ASM General Meeting and ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy). This year’s event is expected to attract more than 10,000 attendees to gain valuable insights from the field’s foremost leaders, interact with multidisciplinary microbiologists, and meet leading product and service providers.

About CytoDyn
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has finished Phase 2 clinical trials with demonstrated antiviral activity in man and is currently in Phase 3. PRO 140 blocks the HIV co-receptor CCR5 on T-cells which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from six Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several weeks of interruption from conventional
drug therapy. CytoDyn intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV and to pursue non HIV indications where CCR5 and its ligand CCL5 may be involved. For more information on the Company, please visit www.cytodyn.com.

About PRO 140
PRO 140 belongs to a new class of HIV/AIDS therapeutics -- viral-entry inhibitors -- that are intended to protect healthy cells from viral infection. PRO 140 is a fully humanized IgG4 monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter T-cells. PRO 140 blocks the predominant HIV (R5) subtype entry into T-cells by masking this required co-receptor, CCR5. Importantly PRO 140 does not appear to interfere with the normal function of CCR5 in mediating immune responses. PRO 140 does not have agonist activity towards CCR5 but does have antagonist activity to CCL5 which is a central mediator in inflammatory diseases. PRO 140 has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects. PRO 140 has been designated a “fast track” product candidate by the FDA. The PRO 140 antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements as compared to daily drug therapies currently in use.

CONTACTS:
Investors:
LHA
Jody Cain
Office: 310-691-7100
E-mail: jcain@lhai.com

Media:
Nader Pourhassan, Ph.D., CEO
Office: 360-980-8524
E-mail: npourhassan@cytodyn.com

Source: CytoDyn Inc.